Summary
Bristol-Myers Squibb Company (BMY) filed an amendment to its 2013 Form 10-K on April 2, 2014, primarily to re-file a revised redacted version of an exhibit related to a confidential treatment request. This amendment does not alter any other disclosures or financial information from the original filing on February 14, 2014. Therefore, investors should refer to the original 10-K for a comprehensive understanding of BMY's financial performance, strategic initiatives, and risk factors for the fiscal year ended December 31, 2013. The original filing indicated BMY's status as a large accelerated filer and a well-known seasoned issuer, with significant market capitalization as of June 30, 2013. Investors should consult the original February 14, 2014 filing for detailed financial statements, management's discussion and analysis, and other critical information pertinent to the company's operational and financial health during that period.
Financial Highlights
57 data points| Revenue | $16.39B |
| Cost of Revenue | $4.62B |
| Gross Profit | $11.77B |
| R&D Expenses | $3.73B |
| SG&A Expenses | $4.94B |
| Operating Expenses | $13.49B |
| Interest Expense | $199.00M |
| Net Income | $2.56B |
| EPS (Basic) | $1.56 |
| EPS (Diluted) | $1.54 |
| Shares Outstanding (Basic) | 1.64B |
| Shares Outstanding (Diluted) | 1.66B |
Key Highlights
- 1This filing is an amendment (10-K/A) to the original Form 10-K filed on February 14, 2014.
- 2The sole purpose of this amendment is to re-file a revised redacted version of Exhibit 10x due to changes in a confidential treatment request.
- 3No other changes have been made to the original filing or any other exhibits.
- 4The amendment does not reflect events occurring after the original filing date and does not modify or update disclosures affected by subsequent events.
- 5Bristol-Myers Squibb Company was a large accelerated filer and a well-known seasoned issuer as of the 2013 fiscal year-end.
- 6The aggregate market value of the company's common stock held by non-affiliates was approximately $73.5 billion as of June 30, 2013.
- 7Investors should refer to the original February 14, 2014 filing for all substantive financial and operational information.